Key Statistics for Pancreatic Neuroendocrine Tumor
Pancreatic neuroendocrine tumors (NETs) are rare. Less than 2% of all cancers found in the pancreas each year are pancreatic NETs.
The number of pancreatic NETs diagnosed each year has been rising over time. This is thought to be partly because they are being found more often incidentally, when imaging tests such as CT or MRI scans of the abdomen are done for other reasons. The ability to distinguish these tumors from other types of cancers in the lab has also improved, leading to more of them being diagnosed.
Most people with pancreatic NETs are older, with the average age of diagnosis being 60. These tumors are slightly more common in men than women.
For statistics related to survival, see Pancreatic Neuroendocrine Tumor Survival Rates by Stage.
Visit our Cancer Statistics Center for more key statistics.
- Written by
- References
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
American Joint Committee on Cancer. Neuroendocrine Tumors of the Pancreas. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
National Cancer Institute. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®). 2022. Accessed at https://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq on January 13, 2023
Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26:3063–3072.
Last Revised: January 13, 2023
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
More in Pancreatic Neuroendocrine Tumors
Help us end cancer as we know it, for everyone.
